Nyxoah S.A. (NASDAQ:NYXH - Get Free Report) shares were up 0.6% on Thursday . The company traded as high as $10.71 and last traded at $10.57. Approximately 35,985 shares were traded during trading, a decline of 25% from the average daily volume of 48,234 shares. The stock had previously closed at $10.51.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on NYXH shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $16.00 target price on shares of Nyxoah in a research note on Tuesday, November 5th. HC Wainwright reissued a "buy" rating and set a $17.00 price objective on shares of Nyxoah in a report on Friday, December 13th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $17.00.
Read Our Latest Research Report on NYXH
Nyxoah Trading Down 0.4 %
The stock's 50 day moving average price is $9.52 and its 200-day moving average price is $8.93. The company has a quick ratio of 4.95, a current ratio of 5.28 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $358.65 million, a PE ratio of -5.63 and a beta of 1.41.
Hedge Funds Weigh In On Nyxoah
Hedge funds and other institutional investors have recently modified their holdings of the stock. Kovack Advisors Inc. purchased a new stake in shares of Nyxoah in the third quarter valued at $96,000. Ameriprise Financial Inc. purchased a new position in Nyxoah during the 4th quarter valued at about $135,000. Vestal Point Capital LP purchased a new position in shares of Nyxoah in the 4th quarter worth approximately $23,394,000. Renaissance Technologies LLC purchased a new position in shares of Nyxoah in the 4th quarter worth approximately $187,000. Finally, Geode Capital Management LLC grew its position in Nyxoah by 19.4% during the 4th quarter. Geode Capital Management LLC now owns 17,100 shares of the company's stock worth $137,000 after purchasing an additional 2,774 shares during the last quarter.
About Nyxoah
(
Get Free Report)
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Read More
Before you consider Nyxoah, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nyxoah wasn't on the list.
While Nyxoah currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
